The In Vitro Toxicology Testing industry is growing rapidly and is expected to continue growing in the foreseeable future. According to a recent study, the global In Vitro Toxicology Testing Market size is projected to reach USD 18.6 billion by 2027 from USD 11.2 billion in 2022, at a CAGR of 10.8% during the forecast period. In vitro toxicology testing refers to the testing of the potential toxicity of a chemical or drug compound in a laboratory environment. It is used to determine the toxic effects of a drug or chemical without the use of animals. This testing provides an alternative to animal testing, which is considered to be unethical. In vitro toxicology testing helps in reducing the cost and time associated with drug development. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065 Latest Trends In Vitro Toxicology Testing Market
Increased use of high-throughput systems: High-throughput systems are becoming increasingly popular for in vitro toxicology testing due to their ability to rapidly generate large amounts of data. This technology can be used to evaluate a wide range of toxicological endpoints, including genotoxicity, cell-based assays, and drug metabolism and pharmacokinetics.
Greater emphasis on 3D cell culture models: Traditional 2D cell culture models have been used for in vitro toxicology testing for many years, but there is an increasing emphasis on 3D cell culture models. This type of model is more physiologically relevant and can provide more accurate data on toxicity.
Use of organ-on-a-chip technology: This technology allows for the testing of drug compounds in a miniaturized system that mimics the function of a real organ. This technology can be used to assess a range of toxicological endpoints, including drug metabolism and absorption, drug-drug interactions, and tissue-specific toxicity.
Development of new in vitro testing methods: New in vitro testing methods are being developed to assess a variety of toxicological endpoints, such as genotoxicity and reproductive toxicity. These methods can be used to identify potential toxic effects of a drug or chemical in a more rapid and cost-effective manner.
Integration of in vitro and in vivo testing: In vitro and in vivo testing are both important tools in toxicology testing, and there is an increasing emphasis on integrating the two. This approach can help to identify potential risks associated with a drug or chemical earlier in the development process.
Opportunities: Increase in toxicology databases open up for companies
The need for speeding up the toxicological assessment of chemicals and using fewer animals and less-expensive tools has strongly stimulated the development of predictive toxicology and structure-based approaches. To make predictive toxicology methods more effective, the field needs access to the largest possible knowledge base of previous toxicology findings, which also needs to be interoperable and comparable. Databases with records of safety profiles of chemicals, their mode of actions, genetic implications, lethal dose information, different formulations, and toxicogenomic information will help promote the efficient use of alternative methods of toxicology testing. These databases will also reduce the repetition of toxicity tests for the same chemicals for safety assessment, ultimately reducing the use of animals for testing. Contributing and sharing data on a common platform will help in understanding the different aspects of toxic substances and the effects of it on a living system. Thus, the development of open, public, and computable toxicology datasets based on standardized and controlled vocabularies will support data management, model building, integrated analysis, validation, and reporting, including regulatory reporting and alternative testing submission requirements, leading to new scientific advances in a mechanistically based predictive toxicology. This will contribute to the growth of the market.
Some of the prominent key players are:
Thermo fisher Scientific, Inc. (US),
Laboratory Corporation of America Holdings (US),
Bio-Rad Laboratories, Inc. (US),
General Electric Company (US),
Eurofins Scientific (Luxembourg),
Merck KGaA (Germany),
Charles River Laboratories International, Inc. (US),
Catalent, Inc. (US) and many more.......
In March 2022, Laboratory Corporation of America Holdings acquired AtlantiCare diagnostic clinical laboratory services.
In September 2021, Laboratory Corporation of America Holdings Acquired Myriad Autoimmune’s Vectra Testing Business, autoimmune business unit, including the Vectra rheumatoid arthritis (RA) assay.
In August 2020, Merck KGaA acquired BSSN Software, a German laboratory informatics company, for ease of data integration, collaboration, analysis, and long-term archiving in laboratories.
In April 2019, Charles River Laboratories acquired Citoxlab, a non-clinical CRO, for USD 494 million (EUR 448 million).
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209577065
The in vitro toxicology testing market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. This is due to the opposition to animal testing resulting in the use of alternate methods, emergence of CROs, growing consumer awareness of product safety, and increasing pharmaceutical drug pipeline, all of which are driving adoption of in vitro toxicology testing in the Asia Pacific.